HYPR - Hyperfine Inc. (HYPR) Q1 2023 Earnings Call Transcript
2023-05-14 06:01:03 ET
Hyperfine, Inc. (HYPR)
Q1 2023 Earnings Conference Call
May 11, 2023 04.30 PM ET
Company Participants
Maria Sainz - President, Chief Executive Officer
Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer
Marissa Bych - Investor Relations, The Gilmartin Group
Conference Call Participants
Larry Biegelsen - Wells Fargo
Vijay Kumar - Evercore ISI
Neil Chatterji - B. Riley
Presentation
Operator
At this time all participants are in listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded.
It is now my pleasure to introduce Marissa Bych from Investor Relations.
Marissa Bych
Great! Thank you for joining today’s call. Earlier today Hyperfine Inc. released financial results for the quarter ended march 31, 2023. A copy of the press release is available on the company’s website as well as sec.gov.
Before we begin, I’d like to remind you that management will make statements during this call that includes forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, expense management, expectations for hiring, training and adoption, growth in our organization, market opportunity, commercial and international expansion, regulatory approvals, and product development are based upon our current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our latest periodic filing with the Securities and Exchange Commission.
This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 11, 2023. Hyperfine, Inc. disclaims any intention or obligation, except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
And with that, I will turn the call over to Maria Sainz, President and Chief Executive Officer.
Maria Sainz
Good afternoon, and thank you all for joining us. On the call with me is our Chief Administrative Officer and Chief Financial Officer, Brett Hale. We achieved measurable growth in the first quarter of 2023, with an all time record revenue of 2.6 million driven by the sale of 10 commercial Swoop systems. In addition, we have continued to execute with a financial discipline that allows our cash runway to extend through the end of 2025. I am pleased with our progress this quarter, and I am confident that we are poised to execute our plan in 2023.
As we mentioned in March, we are focused on three strategic pillars; innovation, clinical evidence and commercial expansion with a strong focus in the US. On innovation, we continue to lead and advance ultra-low MRI with technology iterations and enhancements that further improve image quality as well as the provider and patient experience with Swoop.
In February, we announced the receipt of two FDA 510(k) clearances for Viz.ai powered software updates to the Swoop system. The latest Viz.ai powered software has now been installed in the units in the field. And the feedback from existing users have been very positive especially on the diffusion weighted imaging or DWI sequence.
Our commercial team is now using images in cases with our latest software in their discussions and demos with prospective accounts and feedback has been very positive from prospective users as well. Despite our heightened OpEx discipline, we remain committed to investing in innovation and evidence and we have allocated a healthy budget to R&D through the next several years. We have active development programs working on next generation hardware, additional upgrades to software and Viz.ai for our current critical care application and future stroke pediatrics and neurodegenerative disease use cases.
Furthermore, our partnership with the Bill & Melinda Gates Foundation provides access to a network of leading experts in the field of MRI across the globe, who work in a collaborative manner with our development and clinical science team. On tangible evidence, we are pleased to see abstract papers and symposia focusing on ultra-low-field MRI and the use of our Swoop system at measure scientific calm For instance, like the International Stroke Conference ISC and the American Society of Neuroradiology, ASNR.
At ISC in February, we were pleased to see new clinical research data from Yale, showing the potential for Swoop to provide critical brain imaging following thrombectomy in stroke patients. At ASNR in Chicago last week, we have an interactive case review session with a panel of six leading neuro radiologists, evaluating patients based on Swoop images with our latest software.
This interactive session brought nearly 300 attendees and there was a strong booth traffic at the conference. We also have strong research partnerships with leading institutions working on other applications of the Swoop system in adult and pediatric brain imaging. Our major clinical initiative in 2023 is the Action PMR project.
Action PMR is a global multicenter evaluation that will assess the use of the tube system in the acute ischemic stroke use case and we're fortunate to be working with prominent, experienced and passionate clinical team in the field of stroke. As a reminder, this is an exciting project for us as it represents the first step in pursuing the use of Swoop in acute stroke imaging. We look forward to beginning Action PMR enrollment midyear, and sharing our progress on upcoming call.
Turning to commercial expense. We're pleased with the pipeline of deals driven by our commercial team for 2023 and beyond. The commercial team has also begun implementing our higher pricing and we are encouraged by the solid momentum across multiple territories in the U.S. As we shared in the fall of 2022 we received the purchase order from King's College London for 20 commercial systems in association with the Bill & Melinda Gates Foundation and a signed letter of intent for seven commercial units from BJC Healthcare in St. Louis one of the leading hospital systems in the U.S. to continue to execute the delivery of commercial systems in 2023.
We're very pleased with our new [filled] leadership and commercial structure. Our sales and clinical support teams are in place. And we feel this combination of an experienced capital sales team and a clinical and expert clinical support team is the right approach to drive adoption. The team remains focused on the core U.S. market opportunity building relationships and executing contracts with U.S. hospital systems with a specific focus on multi-system placement opportunities. Clinically our field team remains focused on selling subsystems within the broad critical care opportunity for new imaging while our innovation and clinical evidence teams are setting the stage for much broader use in the future.
Internationally, we maintain our small commercial footprint, but see compelling opportunities for future expansion into new markets. We remain excited about CE marking which we received in February of this year. We also see the immense long term opportunity in low and middle income countries through the work that hospitals affiliated with the Bill & Melinda Gates Foundation are undertaken with Swoop in Africa and Asia. And lastly, we continue to explore the potential to enter the regulatory process in China. All of that said we remain focus on the U.S. as our number one commercial priority for this year.
Finally, as it relates to our commercial process, our commitment to meeting the highest standards for data protection and information security for our customers. We were pleased that in the first quarter of this year, our key platform to achieve the record high trust with space two years certification. We believe this will streamline the information security reviews associated with contracting and hospital implementation.
Now turning to our first quarter results. I'm pleased to announce that we achieved record revenue of 2.6 million and 10 commercial Swoop system placements in the first quarter of 2023 driven in large part by placement to new U.S. customers. I am incredibly proud of our team and remain optimistic in our commercial pipeline for the future. Alongside our three strategic pillars we remain laser focused on spending discipline. We continue to offer [indiscernible] and implement initiatives in support of cash runway extension while investing in innovation, clinical evidence and commercial expansion. We continue to see a cash runway for the business through 2025.
Now turning towards 2023 revenue outlook. We are maintaining our revenue guidance for the full year in the range of $10 million to $14 million. In line with our discipline approach to spending, we're also maintaining guidance for cash burn of $40 million to $45 million for the full year 2023. I want to reiterate from the fundamental of Swoop our access and affordability or commercial progress over the last two years, we know that our clinical value proposition with customers is strong. As mentioned in our last earnings call, we have implemented a new pricing for the Swoop system in early 2023. Our guidance, we placed a gradual continued increase in the two fabric selling price in 2023 relative to 2022.
I will now turn the call over to Brett Hale, our Chief Administrative Officer and Chief Financial Officer to review our first quarter performance and discuss the financial outlook in greater detail.
Brett Hale
Thank you Maria. Turning to our financial results for the first quarter 2023. Revenue for the quarter ended March 31, 2023 was $2.6 million, compared to $1.5 million in the first quarter of 2022. Gross profit for the first quarter of 2023 was $1.2 million compared to $0.1 million in the first quarter of 2022 and reflecting a 44% gross margin. R&D expenses for the first quarter of 2023 were $5.5 million compared to $8.3 million in the first quarter of 2022.
Sales, general and administrative expenses for the first quarter of 2023 were $8.7 million, compared to $15.5 million in the first quarter of 2022. Net loss for the first quarter was $12.2 million, equating to a net loss of $0.17 per share, as compared to a net loss of $23.8 million or a net loss of $0.34 per share for the same period of the prior year.
Our cash burn in the first quarter was $13.4 million, and we ended the first quarter of 2023 with $104 million in cash and cash equivalents. Turning to our 2023 outlook. Based on the progress and current trends of the business, we are maintaining full year expectations for revenue to be in the range of $10 million to $14 million.
As Maria mentioned, the Swoop clinical value proposition with customers is strong. The new pricing is now in effect. As we mentioned last quarter, we will not be providing an exact average selling price per unit volume expectation. But our guidance is predicated on the assumption that the Swoop system pricing will continue increasing in 2023 relative to 2022. And based on our position in the market today, we remain confident in that steady price improvement.
To help you with modeling please note we still expect our second half to be stronger than our first half as our new sales team gains experience and continues to drive the pipeline. For the year we now expect gross margins to be approximately 40% to 50% as we began recognizing scale, and average Swoop pricing moves gradually higher. And lastly, we are maintaining expectations for total cash burn of $40 million to $45 million for the full year 2023.
This incorporates the expectations for continued investment in R&D and substantially streamline investments in SG&A while maintaining customer facing resources to continue to drive the adoption and growth. In line with this we have allocated a greater relative portion of CapEx spending to R&D in 2023 versus prior year at approximately 40% to 50% of total OpEx dollars.
We will continue to focus on our three strategic pillars and maintain spending discipline as we realize the benefits of our recent right sizing and reorganization. As we shared in March, we are excited about the momentum we are building for the remainder of the year and beyond. And we are pleased to have the cash and flexibility to invest in the right areas and afford the business the right runway to execute post reset.
At this point, I'd like to turn the call back to Maria for closing comments.
Maria Sainz
Thank you, Brett. I'm proud of the progress that Hyperfine team has made in weeks and months and I am very bullish as to what this thing can deliver. Just a week ago, I attended ASNR seminar in Chicago and was able to witness firsthand the interests that are suited and it's drawing from clinician as well as the patient's care conversations that continue to open opportunities to Swoop for conventional MRI if not practical or not available. The opportunity for high profile is increasingly compelling as we develop use cases for automotive, MRI and expand geographically. And I am confident that we would have exciting progress to discuss with you all on call to come.
With that I want to thank you for your time and opening up to any questions.
Question-and-Answer Session
Operator
Thank you. [Operator Instructions] Our first question comes from the line of Larry Biegelsen with Wells Fargo.
Larry Biegelsen
Good afternoon. Thanks for taking the question. And congrats on a good start to the year. Just a few for me here. First, you beat consensus and I know they're only a few estimates by about a half a million dollars. And you're on a run right now with over $10 million. So why not raise the low end of the guidance range? Was there anything kind of one time or onetime benefit in Q1. Then I had a couple follow ups?
Maria Sainz
Sure. Thanks for the question. And good afternoon. I think it is really about being prudent. As we said last call, we have just put in place new sales leadership. We have also hired a relatively new sales team. So we're very, I am particularly very, very pleased with the momentum I am seeing with the new reps. But I want to make sure that they have a little bit of more runtime before we start feeling really confident in how they're predicting quarters to come.
There was not anything there that was one time. We have those two orders that we continue to deliver a little bit every quarter and that just continued on the same pattern. So it was a strong company in the U.S. It had a little bit of contribution from international, little bit of contributions from Gates. I just want to make sure that we give our new leadership and then professional, a little bit more runtime until we can be more confident about where we're going to land the plane at the end of the year.
Larry Biegelsen
That's fair. And couple follows one of the Action PMR trial. How long do you think that'll take to enroll? What's the follow up there? How long before we potentially see data?
Maria Sainz
Okay. So it's a little hard to predict. We're doing this as we continue to also improve what I would call our offering on the stroke side. So our first order of business with that evaluation is to make sure that our latest software, which is going to be one more than the one that is commercially available, is able to detect as clinicians want the stroke in the acute setting. We have to do a little bit more work to shorten the time that it takes to gather those sequences, those images. So we need to shorten the length of the sequences. So we will be continuing on that development work and want to actually include faster sequences at some point in time also in the Action PMR.
There really is no follow up to the study, all of it is really in the acute setting. The ability to really detect stroke and be able to get to a clinical decision about what is best for that patient in this evaluation. So no time to wait for follow up data. But I want to be a little bit prudent that our enrollment may take a little longer. So I want to make sure that we have the opportunity to put in the study the latest software, which is now in beta testing, but also faster sequences, which are currently in development and available later in the year.
Larry Biegelsen
That's fair. And just one more for me. There are no to two Alzheimer's drugs that have shown positive data recently. And I think the reimbursement requires four MRIs per year. So I guess my question is, first, are you seeing increased interest in your technology because of that, and what are you doing to capitalize on that opportunity? Do you need to do an equivalent study with standard MRI? Do you need to partner with a company? Love to hear your thoughts on that? Thank you.
Maria Sainz
Excellent question. Thank you, Larry. It definitely is a phenomenal opportunity that has presented in front of us and you are right there is a Biogen drug that got conditional approval a few months ago, should get reimbursed and infusions should start in the fall. And there are even more attractive therapists coming in behind them I believe from Lilly for one and I believe [indiscernible] the third one.
We've gotten ourselves deep in that debate that is right now in the clinical community. We have some current users of our system that believe that we can play a role in that initial triaging of those patients as they are monitored with multiple scans, the number sometimes are even higher than four a year. So we're working at the individual center level. There is also an ASNR working group that has actually focused on this topic, they had a meeting last week and big magnet people where there and so were we. We learning how the field from a clinical perspective is not fully aligned as to whether an ultra-low-field scanner is going to be as effective as a [indiscernible] we're not watching the movie from a distance, we're right in the movies.
We have started to try to reach out to the companies to see if there was an opportunity to partner. And last but not least, we are at the company working to really put together what I would call an Alzheimer's package that may include two things one, maybe a package of sequences, because in we develop sequences separately, and then we also combine them into the protocols that allow people to use them clinical conditions. So that will be one. The other one is that one of the clear trends where there is more alignment from the technical community is that a lot of this discounters are going to be sort of used or read by physicians that are not necessarily your traditional [indiscernible] they are going to be a little bit more in the hands of dementia clinics, professional, memory loss clinic professional, geriatric physicians.
So there is a number of software companies that are looking to standardize sort of trend reports, monitoring reports to really understand how these patients evolve over the course of subsequent diffusion or subsequent doses of the drug. So the short of it is hopefully I've given you a sense that we are big into everything that is happening. I don't know yet and I can't quite paint the picture as to how big the opportunity is for us and how near term it is. But it's definitely something that we're going to push really hard to play a role in and in a few months or quarters, I hope I can give you more clarity as to the size of the opportunity and the timing of it.
Larry Biegelsen
Okay, thank you so much.
Maria Sainz
Of course.
Operator
Thank you. And our next question comes from the line of Vijay Kumar with Evercore ISI.
Kevin Joaquin
Hi, is this Kevin on for Vijay. Just on the gross margin 43% in the quarter can you talk to the drivers behind that number? I know in the past pointed price, volume and costs as the overall driver. But how about from a device versus services perspective? Is there any color provided there and is the about 50% device margin and about 20% service margin [indiscernible] thank you.
Maria Sainz
I think I'm going to let Brett Hale your line was a little hard to understand. So I'll toss it over to Brett.
Brett Hale
Yes, I'll walk through this and clarify if I don't capture the full essence of the question. But the question was effectively on margin and the drivers and were there any sub components. So that so if you look from a progressive basis, we talked about the increase in ASP, if you go back to early 2022, we put new pricing in place that follows into the pricing we had in 2021. We've put new pricing in place here in 2023. Really the most of the margin increase that we've seen sequentially year-over-year is a real direct result of the pricing that we've been able to realize as a business. We do break out the margin or the device and the service components that may vary over time. But really, I think the vast majority of our revenue is coming from device. And you can think about the ASP playing a very heavy role in that. And then I think from [indiscernible] margin, I think we're we've guided to the 40% to 50% range for the full year. So we've landed kind of in the middle of that here for Q1.
Operator
Thank you. [Operator Instructions] And our next question comes from the line of Neil Chatterji with B. Riley.
Neil Chatterji
Hey, guys, thanks for taking the questions. I might have missed this. But just quickly just on the sales funnel installs for the quarter. I know there were some that slipped from fourth quarter. Do we say if any of those hit in first quarter and what's kind of expectations for those?
Maria Sainz
Sorry, I'm not sure I got your question. You were talking about whether things to slip from Q4 and made it into Q1? Maybe repeat it? Sorry.
Neil Chatterji
Yes that and then if and like how that's tracking.
Maria Sainz
Okay. So there were some deals that took a little longer and didn't close in Q4 and ended up actually materializing in Q1. That's a little bit of the nature of the beast, which our deal flow is strong, but [indiscernible] do take longer, we estimate an average of six months. But sometimes they end up taking longer through our safety, scrutiny or cyber scrutiny. I think overall, the quarter will [indiscernible] we also had, as you remember the putting in place of the full sales team. So there was a little bit of a of a choppy quarter in a way we territories with brand new people versus other territories open for a few weeks. So I overall feel that the results in Q1 were very good.
And I feel really good about the pipeline that I see. I don't see the deals taking shorter. But I do see a robust pipeline. And I'm encouraged that it is, as I said before, well distributed across all of our U.S. territories and in some cases, very positive green shoots from some of the newer reps that have seemed to have hit the ground running, although for the most part, we need to give them their six months to really get totally comfortable with their sales process, fermentation process, customer knowledge, customer acquisition and all of the different sub functions within the renewal role.
Neil Chatterji
Got it. Great. And again, sorry, I might have missed this. But on the on the gross margin guidance, the 40 to 50. Just curious on the cadence how to think about that up to this first quarter? Is that going to be sued sequentially stronger through the year? Or how to think about that?
Brett Hale
Yes. I'll take that Neil. This is Brett. So we talked about, I think in our prepared remarks about a gradual increase in pricing throughout the year. And so I think you can think about margins kind of going along with that one with one thing that we've talked about previously is mix does have an impact in terms of any individual quarter. We have three different channels. We've got the U.S. direct commercial. We've got our international distributors, and then we have the units that are part of the KCL Kings College. So any individual quarter may have some variability based on mix, but the general trend and pricing we talked about being sequentially stronger and gradually increasing given the price increases that we've taken in the U.S.
Neil Chatterji
Great. And then just one last one for me just curious if there's any update. It sounds like there was maybe some of them prepared, but just on the visit, sorry, Viz.ai partnership is any progress there.
Maria Sainz
We continue to make progress that we expected. Again, we're gearing towards starting pilot evaluations in accounts with the sort of technology development, which has been around the integration of our images into the workflow and making sure that they can actually use the Viz.ai platform to manage their patients with the use of our images. So I can't give you an exact timeframe as to when we will see go live at the couple of accounts that have been identified, but that continues to move along.
Neil Chatterji
Great. That's it from me. thanks.
Maria Sainz
Thank you.
Operator
Thank you. I would now like to hand the call back over to Hyperfine CEO, Maria Sainz for any closing remarks.
Maria Sainz
Thank you very much for your interest in Hyperfine. I look forward to updating you again in a quarter. Talk to you soon.
Operator
Thank you. Ladies and gentlemen this concludes today's conference call. Thank you for participating and you may now disconnect.
For further details see:
Hyperfine, Inc. (HYPR) Q1 2023 Earnings Call Transcript